COMMUNIQUÉS West-GlobeNewswire

Sharecare to honor extraordinary nurses through The DAISY Foundation’s global recognition program
08/06/2026
Nurses at Sharecare now eligible to be nominated for The DAISY Award for Extraordinary Nurses® by patients, their families, and colleagues, with honorees selected twice per year ATLANTA, June 08, 2026 (GLOBE NEWSWIRE [...]
ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data Supporting the Ongoing Phase 3 STOP-HAE Clinical Trial at the 2026 Annual EAACI Congress
08/06/2026
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that Phase 1/2 clinical data for [...]
Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development
08/06/2026
Advanced analytical services support partners from product characterization and assay development to GMP readiness and clinical manufacturing Intravacc offers state-of-the-art analytical methods for identity, content, [...]
National Action Urged to Address Chronic Pain Crisis Among Women and Women Veterans in Canada
08/06/2026
HAMILTON, Ontario, June 08, 2026 (GLOBE NEWSWIRE) -- A newly released national report is calling for urgent, coordinated action to address chronic pain among women and women Veterans, outlining a roadmap for a pan- [...]
Appel À Une Action Nationale Pour Lutter Contre La Crise De La Douleur Chronique Chez Les Femmes Et Les Vétéranes Au Canada
08/06/2026
HAMILTON, Ontario, 08 juin 2026 (GLOBE NEWSWIRE) -- Un rapport national récemment publié appelle à une action urgente et coordonnée pour lutter contre la douleur chronique chez les femmes et les vétéranes et présente [...]
Alkeus Pharmaceuticals Announces First Patient Dosed in Pivotal Global Phase 3 NORTHSTAR Study of Oral Gildeuretinol in Stargardt Disease
08/06/2026
NORTHSTAR will evaluate the efficacy and safety of investigational oral gildeuretinol, designed to reduce the formation of toxic vitamin A dimers, a proven mechanism of Stargardt disease. The study will assess [...]
Koi Peptides Expands Research Catalog In June 2026
08/06/2026
Wyoming, WY, June 08, 2026 (GLOBE NEWSWIRE) -- Research peptide reference standards in the Koi Peptides laboratory catalog have broadened with the addition of new reference compounds for in vitro analytical use. Each [...]
Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1
08/06/2026
CRPS-RISE designed to support FDA regulatory submission for potential approval of neridronate in patients with CRPS-1 FDA has previously granted neridronate with Breakthrough Therapy, Fast Track, and Orphan Drug [...]
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
08/06/2026
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) [...]
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
08/06/2026
First regulatory approval for Sjögren’s disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant [...]
Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
08/06/2026
Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 FDA 510(k) premarket notification submission RENO, Nev., June 08, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq [...]
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
08/06/2026
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District [...]
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
08/06/2026
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England [...]
Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens
08/06/2026
The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in [...]
Medera Expands Scientific Advisory Board with Leading Heart Failure and Cardiopulmonary Physiology Experts to Advance HFpEF Gene Therapy Program
08/06/2026
Appointments further strengthen clinical leadership as Medera advances its First-In-Human HFpEF gene therapy program toward key upcoming milestones BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a [...]
Sparrow Pharmaceuticals Announces Phase 2a Data Showing Cardiometabolic Benefits of Clofutriben in Adults with Type 2 Diabetes
08/06/2026
Clofutriben improved HbA1c and other cardiometabolic parameters in patients with Type 2 diabetes in a 6-week, placebo-controlled, randomized Phase 2 trial Subset of participants with elevated cortisol (EC) risk factors [...]
Rhea's Factory Wins Global Change Award 2026 for AI-Designed Enzymes Enabling Textile-to-Textile Recycling
08/06/2026
RheaCycle™ transforms polyester waste into virgin-quality building blocks, making circularity commercially viable BERKELEY, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Rhea's Factory, a biotechnology company developing AI [...]
Novo Nordisk A/S - share repurchase programme
08/06/2026
Bagsværd, Denmark, 8 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
08/06/2026
RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the company’s pipeline and [...]

Pages